Trial Profile
An open-label, multicenter study to assess the efficacy of switching to a combination tablet ezetimibe/simvastatin 10mg/40mg, compared to doubling the dose of statin in patients hospitalized with a coronary event
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary)
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms INFORCE
- Sponsors Merck & Co; Organon
- 13 Oct 2012 Planned number of patients changed from 450 to 490.
- 07 Jun 2010 Data from this trial was used in an economic analysis published in Value in Health.
- 24 Oct 2009 Data from the trial was used in an economic analysis presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.